Quand et comment utiliser les inhibiteurs de SGLT2 ou gliflozines en pratique clinique ? Un consensus proposé par la Société francophone du diabète (SFD), la Société française de cardiologie (SFC), le Collège national des cardiologues français (CNCF) et la Société francophone de néphrologie, dialyse et transplantation (SFNDT)
François Diévart, Jean‐Marc Boivin(Inserm), Denis Angoulvant(Université de Tours), Jean‐Michel Halimi(Centre Hospitalier Universitaire de Tours), Gaëtan Prévost(Inserm), Samy Hadjadj(Université de Poitiers), Patrice Darmon(Assistance Publique Hôpitaux de Marseille), Pierre Delanaye(University of Liège)
Cited by 5
Related Papers
An estimated glomerular filtration rate equation for the full age spectrum
|Nephrology Dialysis Transplantation|2016|489
Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate
|Annals of Internal Medicine|2020|400
CKD: A Call for an Age-Adapted Definition
|Journal of the American Society of Nephrology|2019|358
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
Effect of a diabetic environment in utero on predisposition to type 2 diabetes
|The Lancet|2003|286